Allogene Therapeutics, Inc.
9.00%
22,032,040
1737287
019770106
Nov 5, 2025
Feb 13, 2026, 05:09 PM
Reporting Persons (1)
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Pfizer Inc. | CO | 9.00% | 22,032,040 | 22,032,040 | 0 |
Disclosure Items (7)
Common Stock, par value $0.001 per share (the "Common Stock")
Allogene Therapeutics, Inc.
210 East Grand Avenue, South San Francisco, CA, 94080
No amendment to this Item is being made.
The principal business address of Pfizer is 66 Hudson Boulevard East, New York, New York 10001-2192
No amendment to this Item is being made.
No amendment to this Item is being made.
No amendment to this Item is being made.
No amendment to this Item is being made.
The paragraphs captioned (a) - (b) of Item 5 of the Schedule 13D are hereby superseded by the following paragraphs: (a)--(b) The information related to the beneficial ownership of Common Stock by the Reporting Person set forth in Rows 7 through 13 of the cover page hereto is incorporated by reference. The decrease in the percentage of shares of Common Stock held by the Reporting Person reported on this Amendment No. 4 resulted solely from the increase in the number of shares of Common Stock reported as outstanding by the Issuer in the Form 10-Q for the quarterly period ended September 30, 2025 as filed with the U.S. Securities and Exchange Commission on November 6, 2025.
See (a).
The paragraph captioned (c) in the Schedule 13D is hereby supersed by the following paragraph: (c) Except as reported in the Schedule 13D, neither the Reporting Person nor any of the Individuals listed on Schedule I has effected any transactions in the Common Stock during the past sixty (60) days.
No amendment to this Item is being made.
Not applicable.
No amendment to this Item is being made.
Schedule I: Name, business address, present principal occupation or employment and place of citizenship of the directors and executive officers of Pfizer Inc.